Google’s chief health officer Karen DeSalvo announced she will retire this summer. DeSalvo, who likes to introduce herself as ...

Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...

Telehealth company Hims & Hers Health (NYSE:HIMS) announced in Q1 CY2025, with sales up 111% year on year to $586 million.

Hims & Hers Health ( HIMS) shares surged 8% Tuesday, a day after the health and wellness platform posted better-than-expected ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

Ezra's primary competitor is Prenuvo, another full-body MRI scanning startup. In February, Prenuvo announced that it closed a ...

Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to ...